Approval · Notice of Compliance 16166 · 2014
TRIUMEQ: Notice of Compliance 16166
Issued October 9, 2014
A Notice of Compliance is Health Canada’s approval of a drug submission: a new drug, a new use or form, or a change to an approved one. The product itself is in the Drug Product Database, with its current status.
- Notice number
- 16166
- Date
- October 9, 2014
- Company
- Viiv Healthcare UlcMontreal, Quebec, Canada
- Product type
- Prescription Pharmaceutical
- Submission
- New Drug Submission (NDS)
- Submission class
- Other
- Therapeutic class
- Antiretroviral Agent
Products in this notice
| Brand | DIN | Status today |
|---|---|---|
| TRIUMEQ | 02430932 | Marketed |
Medicinal ingredients
- LAMIVUDINE 300 MG per TAB
- ABACAVIR SULFATE 600 MG per TAB
- DOLUTEGRAVIR SODIUM 50 MG per TAB